A new collaboration targeting rare heart diseases has been formed between California’s BioMarin Pharmaceutical…

UK-based Mallinckrodt Pharmaceuticals has ended a trial of INOmax (nitric oxide) gas early due to positive…

The ongoing spread of COVID-19 in Russia is leading to shortages of drugs against orphan diseases in…

A collaboration in COVID-19 between immunology specialist Vir Biotechnology and Alnylam Pharmaceuticals…

India’s Lupin has announced positive top-line results from its pivotal Phase III clinical trial to…

Privately-held pharma and diagnostics firm Menarini Group has announced a definitive agreement to acquire…

A new collaboration between Shanghai’s Junshi Biosciences and Eli Lilly will seek to develop novel…

Specialty chemicals company Evonik has kicked off a major expansion project at two German facilities,…

The US District Court in Delaware issued a decision upholding the validity of patent claims from three…

A pledging conference led by the European Union (EU) has set an initial target of 7.5 billion euros ($8.1…

The COVID-19 pandemic did not stop China from launching its national blockchain-based service network…

Positive top-line data for a pivotal, single-arm, open-label trial of PD-1 inhibitor Libtayo (cemiplimab)…

As with other companies, US drug giant Pfizer and its German partner BioNTech are moving forward their…

Investors in Regeneron could afford a rare smile in these difficult times, as the company’s first quarter…

Shares of US biotech Akebia Therapeutics were up more than 35% at $11.72 by early afternoon today, after…

Almost a year after the original announcement, the US Federal Trade Commission (FTC) has accepted the…

California’s Gilead Sciences has outlined a plan to ramp up production of newly USA-approved COVID-19…

Following a couple of active M&A years, USA-based Alexion Pharmaceuticals has now reached a definitive…

Swiss drugmaker Ferring and its Rebiotix subsidiary have announced a world first with a microbiome-based…

Danish drugmaker Acesion Pharma, which is focused on novel treatments for atrial fibrillation (AF), has…

Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and…

Pandemic-based stockpiling among people with diabetes helped lift revenues beyond analysts’ expectations…

US drugmaker Alexion Pharmaceuticals fared better in its revenue and adjusted earnings figures in the…

The submission of additional information, upon the request of the US regulator, has delayed the action…

Amgen’s Otezla (apremilast), a drug divested by Celgene ahead of its acquisition by Bristol-Myers Squibb,…

Eye health specialist Bausch + Lomb, part Bausch Health Companies, has entered into an exclusive licensing…

Canada-based Bausch Health Companies, along with its wholly-owned subsidiary, Salix Pharmaceuticals and…

Mark Brewer, who heads up the life sciences team at UK broker and M&A advisory company, finnCap, gives…

The fallout from the COVID-19 pandemic has been challenging for many life sciences companies due to a…

GlaxoSmithKline has completed divestment of its Horlicks and other Consumer Healthcare nutrition products…

Late Wednesday, the US Food and Drug Administration said it has granted accelerated approved for Tabrecta…

Privately-held Italian pharma group Mediolanum Farmaceutici has acquired the French immuno-oncology specialist…

Tokyo’s Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) for trastuzumab deruxtecan…

COVID-19 is having varying effects on different markets within healthcare, with drug delivery systems…

Shares of Dr Reddy’s Laboratories rose more than 2% to 3,936.35 rupees, after the Indian drugmaker…

US pharma major Bristol-Myers Squibb saw its revenue reach $10.8 billion in the first quarter of 2020,…

Canada-based BetterLife Pharma, previously known as Pivot Pharmaceuticals, has entered into an agreement…

As had been widely expected, Gilead Sciences on Thursday announced that the Japanese Ministry of Health,…

Italian drugmaker Recordati has reported consolidated revenues for the first quarter of 2020 are 429.2…

The US Food and Drug Administration has granted accelerated approval for Retevmo (selpercatinib) capsules…

US biotech firm jCyte Inc has entered into a licensing agreement with Japanese ophthalmology specialist…

Gilead Sciences scored a massive win earlier this week with its first positive data readout for investigational candidate remdesivir in treating patients with severe COVID-19. Gilead already has its own supply of the drug humming in anticipation of high demand, but opportunities are out there for a partner to join in. 

AbbVie may be working through COVID-19, but it's pressing ahead with its Allergan merger, too—and taking stock of products hit by pandemic lockdowns. That puts Allergan’s aesthetics business top of mind, but AbbVie CEO Rick Gonzalez figures customers are ready and able to return quickly for treatment.

Days after U.S. officials reported the first positive controlled data for Gilead's remdesivir in COVID-19, the FDA has given the drug an emergency use authorization.

Novartis is using familiar faces—real patients from its Cosentyx TV commercials—to thank healthcare workers and promise support for patients. It’s a shift away from product-centered TV ads as Novartis adjusts its Cosentyx DTC effort during the COVID-19 crisis to highlight resources for patients, the drugmaker said.

Roche scored a major win with the FDA's backing for its COVID-19 antibody tests last week in a field marked by products of questionable quality. Now, to cover its booming production goals, Roche plans to infuse nearly half-a-billion dollars into its German manufacturing facility. 

While Gilead has yet to present a marketing plan for remdesivir—much less a price—ICER figures the COVID-19 drug could be cost-effective at up to $4,460 per patient. That means it could easily rake in blockbuster sales this year, at least theoretically.

Gilead made waves on Friday with its emergency FDA approval for remdesivir quickly on the heels of a controlled trial data release. But while it’s an important first step, other COVID-19 medicines will likely be coming down the line, analysts wrote.

Even a pandemic can’t slow down Seattle Genetics and Astellas' new bladder cancer treatment Padcev, which "blew out sales expectations" for the first quarter, analysts said. And now, they're jacking up their long-term sales estimates for the drug as a result.

AbbVie and Allergan have waited for nearly a year for their much-discussed merger to pass muster. Finally, after pushback from consumer groups and tight scrutiny from regulators, the FTC has granted its green light. The partners face just one final hurdle to consummating their deal.